Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)

Next Previous
Trial Profile

A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denifanstat (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms FASCINATE-2
  • Sponsors Sagimet Biosciences

Most Recent Events

  • 10 Nov 2025 According to a Sagimet Biosciences media release, data from the trial presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2025, taking place November 7-11, 2025 in Washington, DC.
  • 07 Oct 2025 According to a Sagimet Biosciences media release, data from the trial will be presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2025, taking place November 7-11, 2025 in Washington, DC.
  • 10 Sep 2025 According to a Sagimet Biosciences media release, company announced that it will give oral presentations and participate in a drug development panel at the 9th Annual MASH Drug Development Summit taking place September 29-October 1, 2025 in Boston, MA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top